Medical Condition News

RSS

Study finds that just 1 high-fat meal can affect your heart health

Eat a breakfast sandwich and your body will be feeling the ill effects well before lunch - now that's fast food!

31 Oct 2012

Bronchial thermoplasty helps control severe asthma

Nearly 24 million people in this country suffer from asthma. For most of them, avoiding allergens and taking medications help keep their asthma under control. But for a small group with severe persistent asthma, frequent hospital visits tend to be the norm and taking medications and lifestyle changes don't do the trick. Northwestern Memorial Hospital is now using a new procedure called bronchial thermoplasty (BT), the first non-drug therapy approved by the Federal Drug Administration, for patients with severe asthma.

31 Oct 2012

Diffusion tensor imaging detects complex muscle structures in 3D

Eindhoven University of Technology (TU/e) and the Academic Medical Center (AMC) in Amsterdam have together developed a technique that allows detailed 3D imaging of complex muscle structures of patients.

31 Oct 2012

Unique bond between SAP102 and GluN2B enables learning and memory

Two proteins have a unique bond that enables brain receptors essential to learning and memory to not only get and stay where they're needed, but to be hauled off when they aren't, researchers say.

31 Oct 2012

Orexo initiates OX51 Phase II trial in patients undergoing prostate biopsy

Swedish specialty pharmaceutical company Orexo today communicated the start of the dose finding study for OX51 in patients undergoing prostate biopsy.

31 Oct 2012

Researchers show how ingesting too much silver can cause argyria

Researchers from Brown University have shown for the first time how ingesting too much silver can cause argyria, a rare condition in which patients' skin turns a striking shade of grayish blue.

31 Oct 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Preeclampsia risk higher for women with Lupus

New research reports that women with systemic lupus erythematosus (SLE) have a two-fold increase in risk of preeclampsia—a dangerous condition in which pregnant women develop high blood pressure (hypertension) and protein in their urine (proteinuria) after 20 weeks of gestation

30 Oct 2012

Breast cancer screening reduces deaths but overdiagnoses

An independent panel of experts has concluded that routine breast cancer screening results in a reduced risk of dying from breast cancer compared to when no screening takes place, but that screening also results in overdiagnosis, according to a Review published in The Lancet.

30 Oct 2012

Top-line results from Neuraltus’ NP001 Phase 2 study on amyotrophic lateral sclerosis

Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).

30 Oct 2012

Sequana Medical announces CE mark approval of alfapump for patients with malignant ascites

Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump system in patients with ascites caused by cancer (malignant ascites).

30 Oct 2012

Poor fitting and inadequate support leading to ineffective use of hearing aids

Twenty per cent of hearing aid users in Norway use the equipment for only an hour each day. The reason is often poor fitting and inadequate support. Now all this could change.

30 Oct 2012

Complix to accelerate development of CPABs against intracellular disease targets

Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders).

30 Oct 2012

STAT3 transcription factor remains in the axon of nerve cells to help prevent neurodegeneration

A study in The Journal of Cell Biology shows how a transcription factor called STAT3 remains in the axon of nerve cells to help prevent neurodegeneration. The findings could pave the way for future drug therapies to slow nerve damage in patients with neurodegenerative diseases.

30 Oct 2012

Lesbian, gay or bisexual cancer survivors more likely to participate in clinical trials

Cancer survivors who self-identified as being lesbian, gay or bisexual were more than twice as likely as heterosexual cancer survivors to have participated in cancer clinical trials, according to data from a small study presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

30 Oct 2012

Sprint Bioscience, TPP partner to develop small molecule inhibitors of choline kinase for cancer

TPP Global Development Ltd (TPP) enters into a collaboration with Sprint Bioscience AB to develop small molecule inhibitors of choline kinase as human therapeutics for the treatment of cancer.

30 Oct 2012

Study identifies new prognostic biomarker and therapeutic target for adult B-ALL

New insight into the aggressive behavior of certain adult B-acute lymphoblastic leukemias has provided researchers with a potential new prognostic biomarker and a promising new therapeutic target.

30 Oct 2012

Adolescent overweight and obesity may increase risk of all-cause ESRD

Being overweight and obese during adolescence appears related to an increased risk of all-cause treated end-stage renal disease (ESRD) during a 25-year period, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

30 Oct 2012

Study suggests 2004 lawsuit fueled big spending on epilepsy drugs

In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses.

30 Oct 2012